EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Vitiligo-like leucoderma following treatment with cyclin-dependent kinase 4 and 6 inhibitors: analysis of clinicopathological and immunohistochemical findings

Maya Engler Markowitz, Rotem Merose, Elena Didkovski, Alon Doron, Amit Iton-Schwartz, Shir Ben Shitrit, Aviv Barzilai, Einav Nili Gal-Yam, Debora Kidron, Amir Sonnenblick, Igor Snast, Daniel Mimouni, Shany Sherman

Clinical and Experimental Dermatology · 2026-02-24 · 51 (3) · 427-434

DOI: 10.1093/ced/llaf482 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Vitiligo-like leucoderma is a rare cutaneous adverse event associated with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. However, its clinicopathological and immunohistochemical profiles remain unclear. Objectives To characterize the clinical, pathological and immunohistochemical features of CDK4/6 inhibitor-induced vitiligo-like leucoderma. Methods This retrospective case series describes five female patients with advanced or metastatic breast cancer who developed vitiligo-like leucoderma during CDK4/6 inhibitor therapy. Clinical data and skin biopsies were evaluated, including immunohistochemical analysis of melanocyte markers, cell-cycle protein (p16) and T-cell subsets. Results The depigmented lesions appeared primarily in sun-exposed areas. Two patients exhibited an inflammatory phenotype with pruritus and a lichenoid rash. In all patients, the lesions progressed rapidly over several months and then stabilized. This course was maintained regardless of any vitiligo-targeted therapeutic interventions. Histopathological examination revealed complete absence of melanocytes in all biopsies. Three specimens (60%) had inflammatory changes, including lichenoid and perivascular lymphohistiocytic infiltrates, with immunohistochemistry showing a predominance of CD4+ T cells within the infiltrates. Features of chronic actinic damage (epidermal atrophy, orthokeratosis, reactive keratinocytes, dermal solar elastosis) were observed. In two biopsies (40%), there was a patchy distribution of p16 staining within basal and suprabasal keratinocytes. Four patients (80%) demonstrated prolonged (2–4 years) progression-free survival. Conclusions CDK4/6 inhibitor-induced vitiligo-like leucoderma appears to be a distinct clinicopathological entity, characterized by a predictable course and stabilization, consistent inflammatory features, and a CD4-predominant immune profile. These findings suggest a unique pathogenic mechanism, either immune-mediated or associated with actinic damage, that distinguishes this condition from classic vitiligo and immune checkpoint inhibitor-induced vitiligo-like leucoderma.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →